<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00687362</url>
  </required_header>
  <id_info>
    <org_study_id>P04528</org_study_id>
    <nct_id>NCT00687362</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)</brief_title>
  <official_title>A Multicenter, Multinational, Open Label Study on the Efficacy and Safety of Infliximab Monotherapy in Moderate-to-severe Chronic Plaque Psoriasis in Middle Eastern Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Middle Eastern subjects with moderate-to-severe chronic plaque psoriasis will be administered
      infusions of infliximab (Remicade) at 5 mg/kg of body weight at Weeks 0, 2, 6, 14, and 22.
      The safety and efficacy of infliximab monotherapy will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2006</start_date>
  <completion_date type="Actual">November 11, 2008</completion_date>
  <primary_completion_date type="Actual">November 11, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psoriasis Area and Severity Index 75 (PASI75) Response at Week 10</measure>
    <time_frame>10 weeks</time_frame>
    <description>PASI 75 response is defined as participants who achieved at least a 75% improvement in PASI score from Baseline to Week 10.
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 to 72 (the higher the number, the worse the disease).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Infliximab 5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.</description>
    <arm_group_label>Infliximab 5 mg/kg</arm_group_label>
    <other_name>Remicade, SCH 215596</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older, either gender, and any race.

          -  Psoriasis affecting &gt;=5% of body surface, PASI score &gt;=10 (maximum score 72).

          -  History of plaque psoriasis for &gt;6 months.

          -  Informed written consent.

          -  Refractory to other anti-psoriasis agents (topical corticosteroids, phototherapy UVa
             [PUVA], or systemic therapy).

          -  Negative chest x-ray and purified protein derivative (PPD) within 1 month.

          -  Understand and be able to adhere to dosing and visit schedules.

          -  Screening laboratory tests must meet protocol-specified criteria.

          -  Women and men of childbearing potential must be using adequate birth control measures
             and should continue such precautions for 6 months after last infusion of infliximab.

        Exclusion Criteria:

          -  Pregnant, nursing, or planned pregnancy within 6 months after last scheduled
             treatment.

          -  Used topical corticosteroids in previous 14 days or systemic therapy (phototherapy UVb
             [UVB], PUVA, cyclosporine, methotrexate) in previous 28 days, or received treatment
             with anti-tumor necrosis factor (TNF)-alpha monoclonal antibodies, human or murine
             immunoglobulins, TNF-alpha receptor fusion proteins, or other bioengineered fusion
             proteins.

          -  Received previous immunobiologics.

          -  Have HIV, hepatitis B or C.

          -  Recently transplanted (exception - corneal transplant &gt;3 months prior to first
             infusion) or known malignancy or history of malignancy within previous 5 years
             (exception - basal or squamous cell carcinoma of skin that has been treated with no
             evidence of recurrence).

          -  Concurrent medications that are not permitted.

          -  congestive heart failure (CHF)

          -  Use of cyclosporine or tacrolimus within 4 weeks prior to Screening.

          -  Use of intramuscular (IM), intravenous (IV), or oral corticosteroids within 4 weeks
             prior to Screening.

          -  Treatment with any investigational drug within 3 months prior to Screening.

          -  Allergy to murine proteins.

          -  Serious infections (hepatitis, pneumonia, pyelonephritis) in previous 3 months.

          -  History of active tuberculosis (TB) requiring treatment within previous 3 years, or
             history of opportunistic infections (herpes zoster) within 2 months of Screening.

          -  Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic,
             hematologic, endocrine, pulmonary, cardiac, neurological or cerebral disease.

          -  Current signs or symptoms of other severe uncontrolled disease which in investigator's
             opinion would put the subject at an unacceptable risk.

          -  History of current alcohol or drug abuse.

          -  Not observed designated washout periods for any of the prohibited medications in
             protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United Arab Emirates</country>
  </removed_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2008</study_first_posted>
  <results_first_submitted>February 17, 2010</results_first_submitted>
  <results_first_submitted_qc>February 17, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 9, 2010</results_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Infliximab 5 mg/kg</title>
          <description>Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19">Completed protocol at Week 24</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Infliximab 5 mg/kg</title>
          <description>Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.05" spread="13.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Middle East</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Psoriasis Area and Severity Index 75 (PASI75) Response at Week 10</title>
        <description>PASI 75 response is defined as participants who achieved at least a 75% improvement in PASI score from Baseline to Week 10.
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 to 72 (the higher the number, the worse the disease).</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infliximab 5 mg/kg</title>
            <description>Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Psoriasis Area and Severity Index 75 (PASI75) Response at Week 10</title>
          <description>PASI 75 response is defined as participants who achieved at least a 75% improvement in PASI score from Baseline to Week 10.
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 to 72 (the higher the number, the worse the disease).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Infliximab 5 mg/kg</title>
          <description>Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>tinea versicolour</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>oropharyngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>psoriasis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI agrees not to publish/publicly present any interim results of the Study without prior written consent of Sponsor. The PI further agrees to
provide 30 days written notice to Sponsor prior to submission for publication/presentation to allow Sponsor to review materials which report any results of the Study. Sponsor shall have the right to review/comment on
any presentation, which include editorial rights to ensure protection of confidential information, accuracy, and fair balance.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

